Large pharma dealmaking activity has been significant from Jan 2018 to May 2024, with M&A premiums increasing over time and hitting a high in 2023. Royalty Pharma acquired rights to Agios' 15% royalty on potential vorasidenib U.S. net sales for $905M upfront upon FDA approval, boosting Agios' financial independence for future launches and pipeline expansion.
Agios cashes in on cancer drug again with $905M Royalty Pharma deal https://t.co/NbvLbZhC6Z by @Lilah_Alvarado $AGIO $RPRX
In the last week: —Agios Pharmaceuticals announced a $905 million purchase with Royalty Pharma —Pheon Therapeutics raised a $120 million Series B —SixPeaks Bio came out of stealth with $110 million in funding. https://t.co/STi6B50cQd
Huge congrats to the entire @AgiosPharma team for a fabulous deal with Royalty Pharma https://t.co/QvvjAZJpnt
$AGIO - Royalty Pharma to acquire rights to Agios’ 15% royalty on potential vorasidenib U.S. net sales for $905M upfront upon FDA approval https://t.co/AalHnJiOHh
Agios has agreed to sell rights to our 15% royalty on potential U.S. net sales of Servier’s vorasidenib to Royalty Pharma. This deal boosts our financial independence for future PYRUKYND® launches and pipeline expansion. https://t.co/9YjSOTiUD0 https://t.co/fulq9NPqIs
Large pharma revenue growth comes largely from M&A. $XBI https://t.co/ETJvYKEMf5
Biotech/pharma M&A premiums vs. day before public price has been steadily increasing over time & hit an all-time high in 2023. $XBI @EYnews https://t.co/hUkep4Ckts
🤝Large Pharma Dealmaking Activity Jan 2018 to May 2024 Source: Stifel / DealForma https://t.co/Z9lpkAfIfX